In this study, EGFR mutant NSCLCs have significantly lower PD-L1 expression, but those without EGFR mutation have higher levels of PD-L1, TP53 mutation, and MET activation; patients with EGFR WT NSCLC who overexpress PD-L1 are statistically more likely to also overexpress MET and have mutated TP53. The gene discussed is MET; the disease is non-small cell lung carcinoma.